Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus
Brief Summary: This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.


Options:
A: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
B: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide
C: Arm Label: Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Depatuxizumab mafodotin, Radiation: Radiation | Arm Label: Placebo, Radiation and TMZ; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation, Drug: Placebo for ABT-414 | Arm Label: Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide, Drug: Depatuxizumab mafodotin, Radiation: Radiation | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ, Placebo, Radiation and TMZ | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ), Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ, Placebo, Radiation and TMZ | Intervention Type: DRUG; Name: Placebo for ABT-414; Assigned to Arm(s): Placebo, Radiation and TMZ
D: Arm Label: PF-02341066; Type: EXPERIMENTAL; Interventions: Drug: PF-02341066 | Arm Label: Pemetrexed or Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Docetaxel | Intervention Type: DRUG; Name: PF-02341066; Assigned to Arm(s): PF-02341066 | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed or Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pemetrexed or Docetaxel

Answer: D